“According to the info we have viewed during the TRIDENT-one demo, repotrectinib has the potential to become a completely new regular of care choice for patients with locally Innovative or metastatic ROS1 fusion-beneficial lung cancer.”Eisai and Biogen have already been collaborating around the joint progress and commercialization of Advertisem